A5038819739- Advanced Radiotherapy Techniques
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Medical Imaging Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Radiation Therapy and Dosimetry
- Radiation Dose and Imaging
- Glioma Diagnosis and Treatment
- Advances in Oncology and Radiotherapy
- Bladder and Urothelial Cancer Treatments
- Lung Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Sarcoma Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Advanced X-ray and CT Imaging
- Statistical Methods in Clinical Trials
- Colorectal Cancer Surgical Treatments
- Brain Metastases and Treatment
- Management of metastatic bone disease
- Economic and Financial Impacts of Cancer
- Effects of Radiation Exposure
- Vascular Tumors and Angiosarcomas
- Lung Cancer Treatments and Mutations
- MRI in cancer diagnosis
- Global Cancer Incidence and Screening
Washington University in St. Louis
2016-2025
Mallinckrodt (United States)
2002-2023
Emory University
2010-2023
Nebraska Cancer Specialists
2023
Jewish Hospital
2014-2022
Barnes-Jewish Hospital
1997-2022
Ferrer Grupo (Spain)
2020
Economic History Society
2020
Junshin Gakuen University
2019
SRM Institute of Science and Technology
2019
We sought to identify determinants of health-related quality life after primary treatment prostate cancer and measure the effects such on satisfaction with outcome in patients their spouses or partners.
An increasing serum prostate-specific antigen (PSA) level is the initial sign of recurrent prostate cancer among patients treated with radical prostatectomy. Salvage radiation therapy (SRT) may eradicate locally cancer, but studies to distinguish local from systemic recurrence lack adequate sensitivity and specificity. We developed a nomogram predict probability control at 6 years after SRT for PSA-defined recurrence.Using multivariable Cox regression analysis, we constructed model disease...
Purpose Conventional radiotherapy (C-RT) treatment schedules for patients with prostate cancer typically require 40 to 45 treatments that take place from > 8 9 weeks. Preclinical and clinical research suggest hypofractionation—fewer but at a higher dose per treatment—may produce similar outcomes. This trial was designed assess whether the efficacy of hypofractionated (H-RT) schedule is no worse than C-RT in men low-risk cancer. Patients Methods A total 1,115 were randomly assigned 1:1...
You have accessJournal of UrologyAUA Guideline1 Aug 2013Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Guidelineis companion ofAdjuvant Versus Post-Prostatectomy Radiation Therapy: A Critical Review the Evidence Ian M. Thompson, Richard K. Valicenti, Peter Albertsen, Brian J. Davis, S. Larry Goldenberg, Carol Hahn, Eric Klein, Jeff Michalski, Mack Roach, Oliver Sartor, Stuart Wolf, Martha Faraday ThompsonIan Thompson , ValicentiRichard Valicenti AlbertsenPeter Albertsen...
Purpose/objectivesSBRT is used to treat oligometastatic or unresectable primary abdominal malignancies, although ablative dose delivery limited by proximity of organs-at-risk (OAR). Stereotactic, magnetic resonance (MR)-guided online-adaptive radiotherapy (SMART) may improve SBRT's therapeutic ratio. This prospective Phase I trial assessed feasibility and potential advantages SMART malignancies.Materials/methodsTwenty patients with liver (n = 10) non-liver malignancies underwent SMART....
Purpose: The objective of this work was to develop a quality control (QC) tool reduce intensity modulated radiotherapy (IMRT) planning variability and improve treatment plan using mathematical models that predict achievable organ‐at‐risk (OAR) dose‐volume histograms (DVHs) based on individual patient anatomy. Methods: A framework OAR DVHs derived the correlation expected dose minimum distance from voxel PTV surface. voxels sharing range distances were computed as subvolumes. three‐parameter,...
Perirectal spacing, whereby biomaterials are placed between the prostate and rectum, shows promise in reducing rectal dose during cancer radiation therapy. A prospective multicenter randomized controlled pivotal trial was performed to assess outcomes following absorbable spacer (SpaceOAR system) implantation.Overall, 222 patients with clinical stage T1 or T2 underwent computed tomography (CT) magnetic resonance imaging (MRI) scans for treatment planning, followed fiducial marker placement,...
We aimed to update a previously published, multi-institutional nomogram of outcomes for salvage radiotherapy (SRT) following radical prostatectomy (RP) prostate cancer, including patients treated in the contemporary era.Individual data from node-negative with detectable post-RP prostate-specific antigen (PSA) SRT or without concurrent androgen-deprivation therapy (ADT) were obtained 10 academic institutions. Freedom biochemical failure (FFBF) and distant metastases (DM) rates estimated,...
PurposeSpaceOAR, a Food and Drug Administration–approved hydrogel intended to create rectal–prostate space, was evaluated in single-blind phase III trial of image guided intensity modulated radiation therapy. A total 222 men were randomized 2:1 the spacer or control group received 79.2 Gy 1.8-Gy fractions prostate with without seminal vesicles. The present study reports final results median follow-up period 3 years.Methods MaterialsCumulative (Common Terminology Criteria for Adverse Events,...
<h3>Context</h3>Sexual function is the health-related quality of life (HRQOL) domain most commonly impaired after prostate cancer treatment; however, validated tools to enable personalized prediction erectile dysfunction treatment are lacking.<h3>Objective</h3>To predict long-term following based on individual patient and characteristics.<h3>Design</h3>Pretreatment characteristics, sexual HRQOL, details measured in a longitudinal academic multicenter cohort (Prostate Cancer Outcomes...
<h3>Importance</h3> Optimizing radiation therapy techniques for localized prostate cancer can affect patient outcomes. Dose escalation improves biochemical control, but no prior trials were powered to detect overall survival (OS) differences. <h3>Objective</h3> To determine whether dose 79.2 Gy compared with 70.2 would improve OS and other outcomes in cancer. <h3>Design, Setting, Participants</h3> The NRG Oncology/RTOG 0126 randomized clinical trial 1532 patients from 104 North American...
Robert D. Timmerman, MD; Rebecca Paulus, BS; Harvey I. Pass, Elizabeth M. Gore, Martin J. Edelman, James Galvin, DSc; William L. Straube, MS; Lucien A. Nedzi, Ronald C. McGarry, MD, PhD; Cliff G. Robinson, Peter B. Schiff, Garrick Chang, Billy W. Loo Jr, Jeffrey Bradley, Hak Choy, MD
Patients with metastatic rhabdomyosarcoma (RMS), except those younger than 10 years embryonal RMS, have an estimated long-term event-free survival (EFS) of less 20%. The main goal this study was to improve outcome patients RMS by dose intensification interval compression, use the most active agents determined in phase II window studies, and irinotecan as a radiation sensitizer.Patients received 54 weeks therapy: blocks therapy vincristine/irinotecan (weeks 1 6, 20 25, 47 52), compression...